Investec Bank Plc (INVP.L) acquired 9,580 ordinary shares in Advanced Medical Solutions Group Plc (AMS.L) at a uniform price of 282.75 pence per share on 28th October 2026.
The transaction, executed at a single consistent price across the entire order, was disclosed publicly the following day under Rule 8.5 of the UK Takeover Code.
Advanced Medical Solutions Group shares edged down 0.18% around the time of disclosure, while Investec itself traded modestly higher, gaining 0.16% on the London market.
Investec holds a dual role in relation to Advanced Medical Solutions, serving simultaneously as both financial adviser and joint broker to the medical technology company.
That relationship places the bank in the category of an exempt principal trader with recognised intermediary status, requiring it to file dealings conducted in a client-serving capacity.
The Form 8.5 filing confirms no cash-settled derivative transactions were undertaken alongside the share purchase, nor were any stock-settled derivatives or options involved.
Investec also disclosed that no indemnity arrangements, option agreements, or understandings relating to voting rights or future acquisition of relevant securities are in place.
The filing was submitted to a Regulatory Information Service in line with mandatory public disclosure obligations that apply to all parties dealing during a relevant offer period.
Contact for the disclosure was listed as Priyali Bhattacharjee, with a telephone number registered in India, reflecting Investec’s international operational structure.
The Takeover Panel’s Market Surveillance Unit oversees compliance with Rule 8 dealing disclosure requirements, providing consultation to market participants navigating the reporting framework.
Advanced Medical Solutions Group, a UK-listed wound care and surgical products manufacturer, has been subject to the heightened transparency rules that accompany formal offer-period scrutiny.
Regulatory filings of this nature are designed to give the market full visibility into the trading activity of advisers and brokers who may possess material non-public information about a target company.
